The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
The phase III GRAVITAS-301 study did not meet its primary endpoint of improving overall response rate (ORR)
The randomized, double-blind, placebo-controlled pivotal phase III study, GRAVITAS-301 (NCT03139604), aimed to evaluate itacitinib (a novel and selective JAK1 inhibitor) versus placebo, both in combination with corticosteroids, as a first-line treatment in patients with treatment-naïve acute graft-versus-host disease.
On the 2nd January 2020, a press release announced that GRAVITAS-301 did not meet the primary endpoint of improving overall response rate (ORR) at Day 28. The improvement in the ORR at Day 28, observed in the itacitinib arm versus the placebo arm (74% vs 66.4%, respectively; p= 0.08), was not statistically significant. The key secondary endpoint was non-relapse mortality at Month 6, and no difference was observed between the treatment and placebo arms.
The most common adverse events observed in GRAVITAS-301 were thrombocytopenia and anemia (34.9% vs 34.7% and 29.8% vs 25% in the itacitinib arm vs the placebo arm, respectively).
References